<DOC>
	<DOCNO>NCT00000946</DOCNO>
	<brief_summary>The purpose study test three experimental HIV vaccine . This study look whether safe give vaccine together immune system respond vaccine . There number study perform test HIV vaccine . The vaccine seem promise canarypox vaccine , know ALVAC vaccine . The three experimental HIV vaccine use study call ALVAC-HIV vCP205 , HIV-1 SF-2 p24 , HIV-1 SF-2 rgp120 . The HIV-1 SF-2 p24 HIV-1 SF-2 rgp120 vaccine mixed adjuvant , substance increase immune response .</brief_summary>
	<brief_title>A Study Test Safety Three Experimental HIV Vaccines</brief_title>
	<detailed_description>There currently several Phase I II clinical trial perform within AVEG evaluate different HIV-1 vaccine candidate . The HIV-1 vaccination approach furthest along clinical development pathway so-called prime-boost regimen live recombinant canarypox priming ( ALVAC-HIV vCP205 ) recombinant subunit protein boost ( HIV-1 SF-2 rgp120 MF59 adjuvant ) . The protein boost enhances neutralize antibody response laboratory strain HIV-1 assay perform vitro , well enhance CD4 cell response increase frequency CD8 cytotoxic T lymphocytes ( CTLs ) . In ALVAC-HIV trial prime-boost regimen complete date , protein boost HIV-1 SF-2 rgp120 subunit protein . This study design explore whether boost live recombinant canarypox vaccination novel protein subunit , recombinant HIV-1 SF-2 p24 , enhance CD4 CD8 cell response direct HIV-1 antigen . Volunteers randomize 1 5 group . All volunteer receive total 4 immunization , administer Months 0 , 1 , 3 , 6 . Each group receive different combination vaccine follow : Group 1 : ALVAC-HIV vCP205 plus HIV-1 SF-2 p24 . Group 2 : ALVAC-HIV vCP205 plus MF59 adjuvant citrate vehicle ( control HIV-1 SF-2 p24 HIV-1 SF-2 rgp120 ) Months 0 1 ; ALVAC-HIV vCP205 plus HIV-1 SF-2 p24 month 3 6 . Group 3 : ALVAC-HIV vCP205 plus control Months 0 1 ; ALVAC-HIV vCP205 plus HIV-1 SF-2 p24 combine HIV-1 SF-2 rgp120 Months 3 6 . Group 4 : ALVAC-HIV vCP205 plus control Months 0 1 ; ALVAC-HIV vCP205 plus HIV-1 SF-2 rgp 120 Months 3 6 . Group 5 : ALVAC-RG vCP65 ( control ALVAC-HIV vCP205 ) plus control Months 0,1,3 , 6 . The study last approximately 18 month ; patient receive clinical evaluation measure vaccine safety 11 study visit specify time interval .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are age 18 60 . Are HIVnegative . Are negative Hepatitis B . Have normal physical exam . Are available 18 month followup . Agree use effective method birth control 1 month receive vaccine study . Exclusion Criteria You eligible study : Have history immunodeficiency , chronic illness , cancer . Have medical psychiatric condition would make unable comply study . Are higherrisk HIV infection ; example , history injection drug use past year practice high risk sexual behavior . Have syphilis tuberculosis . Have receive live vaccine past 60 day , ever receive HIV vaccine placebo previous HIV vaccine study , ever receive rabies vaccine . Have history serious allergic reaction vaccine substance , include neomycin egg product . Have receive certain medication . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>